Business
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.","length":446,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Pipeline Highlights","length":19,"tagName":"p"},{"type":"text","content":"HT-001 (Topical Epidermal Growth Factor Inhibitor) – Phase 2 CLEER-001 Trial Advancing","length":86,"tagName":"p"},{"type":"text","content":"Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care.","length":168,"tagName":"p"},{"type":"text","content":"Recent progress includes:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strong safety profile to date with no dose-limiting toxicities observed.","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Consistent improvement trends in rash severity and pruritus","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased clinical-site engagement and favorable investigator feedback.","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":202,"olType":false},{"type":"text","content":"A further clinical update is anticipated in the coming months as enrollment continues to progress.","length":98,"tagName":"p"},{"type":"text","content":"HT-KIT (Orphan Drug Designation for Mast Cell Diseases)...